Drug Patents owned by Melinta Therap
1. List of Kimyrsa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9649352 | MELINTA THERAP | High purity oritavancin and method of producing same |
Jul, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420592 | MELINTA THERAP | Methods of treatment using single doses of oritavancin |
Aug, 2029
(6 years from now) | |
| US9682061 | MELINTA THERAP | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 12, 2024 |
| New Chemical Entity Exclusivity (NCE) | Aug 6, 2019 |
| Generating Antibiotic Incentives Now (GAIN) | Aug 6, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 2023-08-07
Market Authorisation Date: 12 March, 2021
Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent
Dosage: POWDER;INTRAVENOUS
KIMYRSA family patents
14
United States
4
China
4
European Union
3
Canada
3
Japan
3
Australia
2
New Zealand
2
Brazil
2
EA
2
Mexico
2
Hungary
1
Poland
1
Spain
1
Netherlands
1
Hong Kong
1
Norway
1
Denmark
2. List of Orbactiv drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420592 | MELINTA THERAP | Methods of treatment using single doses of oritavancin |
Aug, 2029
(6 years from now) | |
| US9682061 | MELINTA THERAP | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(6 years from now) | |
| US9649352 | MELINTA THERAP | High purity oritavancin and method of producing same |
Jul, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 6, 2019 |
| Generating Antibiotic Incentives Now (GAIN) | Aug 6, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 2023-08-07
Market Authorisation Date: 06 August, 2014
Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections
Dosage: POWDER;INTRAVENOUS
ORBACTIV family patents
14
United States
4
China
4
European Union
3
Canada
3
Japan
3
Australia
2
New Zealand
2
Brazil
2
EA
2
Mexico
2
Hungary
1
Poland
1
Spain
1
Netherlands
1
Hong Kong
1
Norway
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic